Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts at Tertiary Care Hospital in Karachi.

Identify the effects of combined intralesional furosemide 20mg/2ml and digoxin 0.5mg/2ml in cutaneous warts given weekly are rather safe and effective treatment for cutaneous warts, focusing on their effectiveness and safety, at a tertiary care hospital in Karachi, Pakistan.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Cutaneous Warts

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Jinnah Postgraduate Medical Centre

Karachi, Sindh, 75500, Pakistan

About this study

Cutaneous warts are benign growth caused by human papilloma virus. Virus have more than 100 types of which few are responsible for cutaneous disease. Both injection furosemide and digoxin cause decrease intracellular potassium levels by interacting with cell membrane ion co-transporters (Na+/K+-ATPase and Na+-K+-2Cl-co-transporter-1) thereby causing delay in viral replication. The purpose of study is to evaluate the effects of both furosemide and digoxin given 0.2 ml once weekly for five weeks on viral warts.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients presenting with greater than or equal to two warts
Either gender.
Age 18 - 60 years. -

Exclusion criteria

Pregnant or lactating women.
Patient not giving informed consent.
Patient received any treatment in the last 3 months period.
Patient with acute illness and immuno-suppressive disease.
Patient taking immuno-suppressive drugs.
Patient having hypersensitivity to any investigational medicine.
Patient having cutaneous warts on face and genitals.
Patient having cardiovascular disease.
Patient having renal disease. -

Treatment and study plan

Furosemide

Drug

Furosemide 20mg/2ml and digoxin 0.5mg/2ml given 0.2 ml into the wart base once weekly for 5 weeks

Other names: Digoxin

Primary outcomes

Size of cutaneous wart

Time frame: 5 weeks

Change in the dimensions of cutaneous wart assessed by Physician's wart assessment scale weekly and through photographs taking at the start and end of the study.

Sponsors and collaborators

Lead sponsor

Jinnah Postgraduate Medical Centre

Other Gov

Registry information

Official study title

Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts.

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Feb 12, 2025
Registry last updated: Feb 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed